ABC Study: 5-Yr Survival Outcomes With Nivolumab ± Ipilimumab in Patients With Melanoma Brain Metastases

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
An update of the ABC study at 5 years shows that nivolumab plus ipilimumab has enduring activity in patients with asymptomatic melanoma brain metastases.
Format: Microsoft PowerPoint (.ppt)
File Size: 415 KB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings